Miquel Vila Bover I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR) Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca Miquel Vila Bover Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)
I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder. In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN). I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.
Líneas de investigación Neuromelanin and Parkinson's disease In Parkinson's disease (PD), there is a selective degeneration of neurons that contain a dark-brown pigment called neuromelanin, especially dopaminergic neurons of the substantia nigra, which leads to the classical motor symptoms of the disease. However, the physiological significance of neuromelanin and its potential contribution to PD pathogenesis remain unknown. IP: Miquel Vila Bover Identification of biomarkers of prodromal Parkinson's disease Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments. IP: Miquel Vila Bover, Ariadna Laguna Tuset Regeneration of dopaminergic neurons in Parkinson's disease via cell fusion-mediated reprogramming Co-PI: Pia Cosma, CRG.Given the current lack of disease-modifying therapies for Parkinson’s disease (PD), we are exploring whether cell-fusion-mediated regeneration of dopaminergic neurons can be achieved, for therapeutic purposes, in experimental animal models of PD after transplantation of Wnt-activated haematopoietic stem and progenitor cells (HSPCs). IP: Miquel Vila Bover Pathogenic role of autophagic/lysosomal dysfunction in Parkinson's disease Autophagy is the degradation of intracellular components inside the lysosomes and it is essential for the maintenance of cellular homeostasis and neuronal viability. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: - Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity.- Development of new autophagy pharmacological modulators (mTOR-independent) as a therapeutic strategy in neurodegenerative diseases. IP: Marta Martínez Vicente, Miquel Vila Bover Paginación Página actual 1 Página 2 Siguiente página › Última página » Proyectos Interacción patogénica entre la acumulación de neuromelanina y factores de susceptibilidad a la enfermedad de Parkinson: rol en el inicio y progresión de la enfermedad (NeuromelaninPD) IP: Miquel Vila Bover Colaboradores: Javier Hoyo Pérez, Laura Diez Salvatierra, Gerard Roch Alba, Marta González Sepúlveda, Annabelle Parent Entidad financiadora: Ministerio Ciencia, Innovación y Universidades Financiación: 337500 Referencia: PID2024-159556OB-I00 Duración: 01/09/2025 - 31/08/2028 Neuromelanin and PD: mechanisms and therapeutic perspectives IP: Miquel Vila Bover Colaboradores: - Entidad financiadora: Michael J. Fox Foundation Financiación: 441200 Referencia: NEUROMELANIN-PD_M.VILA_MJFF2025 Duración: 01/07/2025 - 30/06/2027 Neurodegeneratives IP: Miquel Vila Bover Colaboradores: - Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 160000 Referencia: VILA/BOOST/2024 Duración: 15/11/2024 - 14/11/2028 Red de Investigación MitoNED: (Dis)función mitocondrial en enfermedades neurodegenerativas IP: Miquel Vila Bover Colaboradores: - Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 0.01 Referencia: RED2022-134786-T Duración: 01/06/2023 - 31/05/2025 Paginación Página actual 1 Página 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »